For how we live.
An FDA advisory committee will meet on 30 October to review Sydnexis's atropine sulfate 0.01% eye drops, proposed to slow myopia progression in children aged 3 and older. The public docket closes 29 October.
Open-angle glaucoma steals side vision so slowly that half of people who have it don't know. There is no way to prevent it — but a placebo-controlled trial showed pressure-lowering drops preserve vision.
Floaters are usually ageing changes in the eye's gel. But among people who suddenly develop floaters and flashes, about 14% turn out to have a retinal tear — which can lead to permanent vision loss if left.
Eye exercises won't sharpen blurry sight or cure nearsightedness — glasses and surgery do that. But one focusing problem, convergence insufficiency, does respond: an office-based programme helped 73% in a trial.
By age 80 most people have a cataract or have had one removed. You can lower some risks, but the antioxidant vitamins tested in a 4,629-person trial did not slow them, and surgery is the only cure.
The Essilor-designed HAL lenses cut two-year myopia progression by 71% versus ordinary glasses in 159 American children. The company employs the study's authors, and the result backs the device's US clearance.
Reading in poor light makes eyes feel tired, but there is no evidence it causes lasting damage. What really shapes eyesight is near-work load and time in bright daylight — and it acts in childhood.
About a quarter of people sneeze on stepping into bright light. It runs in families, has been tied to specific gene variants, and looks like visual signals spilling into the sneeze circuit.
The advice to look 20 feet away for 20 seconds every 20 minutes is everywhere. A two-week trial in symptomatic computer users found it cut eye-strain and dry-eye symptoms, but changed no measurable sign of eye health.
Across 17 randomised trials, blue-light filtering lenses showed no clear benefit for eye strain, vision or sleep. The evening-screen problem they target is real; this is not the fix.
An autonomous AI for diabetic retinopathy hit 87.2% sensitivity in primary care. A smartphone acuity test agreed with a reference chart to within 0.07 logMAR. Both are triage, not diagnosis.
Cataract surgery was tied to 29% lower dementia risk in a strong cohort. But the largest hearing-aid trial found no overall effect on cognition. The signal is real; the proof that fixing senses prevents dementia is not.
Serious contact-lens eye infections are uncommon in absolute terms, but overnight wear is the single largest modifiable risk factor. The rare cases can scar the cornea and cost vision.
The trials that made eye vitamins a standard recommendation enrolled only people who already had substantial disease. In AREDS2, neither omega-3 nor lutein beat placebo on the primary endpoint.
Eye strain is close to universal among heavy device users, and it is temporary. The evidence that screen time causes myopia is real but weak, and every study of it measured screen time by questionnaire.
Cochrane's living review of 104 trials rates high-dose atropine and orthokeratology moderate certainty. The low-dose atropine most widely used sits at very low certainty, and two Western trials disagree.
Reviews put patient satisfaction around 95 percent. FDA-collaborative studies also found that a large minority reported new glare, halos or dry eyes afterward — two true findings that must be held together.
A cluster-randomised trial in Guangzhou cut three-year myopia incidence by 9.1 percentage points with 40 extra minutes outdoors a day. The eye's underlying growth barely changed.